Full video transcriptClick to expand
Auto-generated transcript of @landotalkspeps's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Alright, this is gonna be the only IGF-103 video you're ever gonna have to watch again
- 0:03because I'm gonna explain everything when it comes to starting IGF-103.
- 0:07First off, if you don't know what IGF-103 is, it's a path that works directly at muscle
- 0:10cell level.
- 0:11It's gonna bind with your IGF-1 muscle receptors, sending nutrients directly to muscle tissue,
- 0:15enhancing protein synthesis, signaling hypertrophy pathways, building muscle, size, and strength.
- 0:21At first starting IGF-103, people typically start in the range of 20 to 40 micrograms
- 0:24for that first week, seeing how their body responds, and if they respond well, they typically
- 0:28increase to around 60 to 80 micrograms for the rest of their cycle.
- 0:32The most common cycle length is 8 weeks on, then 8 weeks off.
- 0:35When it comes to timing, people typically take it post-workout because that's when your
- 0:38muscles are most insulin sensitive and blood flow is high, so your muscles are gonna respond
- 0:42and nutrients a lot better.
- 0:43For reconstitution, it usually comes in a 1 milligram vial, so reconstituting with 1
- 0:47milliliter back to your esthetic water makes it very easy.
- 0:49At the end of the day, IGF-103 is a tool to amplify what your body's already doing correctly,
- 0:54so if you're not incorporating good habits when it comes to overall training, nutrition,
- 0:57and recovery, you're not gonna be able to optimize your results.
- 1:00Reminder, this is not medical advice, this is for educational purposes only.
Gym peptides on TikTok: separating hype from human data
Quick answer
The creator describes a compound called IGF-103 as an IGF-1 receptor agonist promoting muscle protein synthesis and hypertrophy, but this compound name does not correspond to any identified peptide in peer-reviewed literature or regulatory databases. The dosing and cycle protocol presented (20 to 80 micrograms over 8 weeks) has no published human clinical trial supporting its safety or efficacy. Any product sold under this name in the gray market carries an unquantifiable risk of mislabeling, contamination, or misrepresentation of its actual pharmacological identity.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 4 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Gym peptides on TikTok: separating hype from human data, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Gym peptides on TikTok: separating hype from human data is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Gym peptides on TikTok: separating hype from human data" from Lando. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator describes a compound called IGF-103 as an IGF-1 receptor agonist promoting muscle protein synthesis and hypertrophy, but this compound name does not correspond to any identified peptide in peer-reviewed literature or regulatory databases.
The reason this review is not generic is the source wording and the canonical claim label "peptides not medical advice educational only fyp trending gym gymtok." In this clip, the useful excerpt is: "Alright, this is gonna be the only IGF-103 video you're ever gonna have to watch again because I'm gonna explain everything when it comes to starting IGF-103." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Ipamorelin, the first selective growth hormone secretagogue (1998), The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation (2001), and Influence of chronic treatment with the growth hormone secretagogue Ipamorelin (2002), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator describes a compound called IGF-103 as an IGF-1 receptor agonist promoting muscle protein synthesis and hypertrophy, but this compound name does not correspond to any identified peptide in peer-reviewed literature or regulatory databases.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator describes a compound called IGF-103 as an IGF-1 receptor agonist promoting muscle protein synthesis and hypertrophy, but this compound name does not correspond to any identified peptide in peer-reviewed literature or regulatory databases. The dosing and cycle protocol presented (20 to 80 micrograms over 8 weeks) has no published human clinical trial supporting its safety or efficacy. Any product sold under this name in the gray market carries an unquantifiable risk of mislabeling, contamination, or misrepresentation of its actual pharmacological identity.
- The compound 'IGF-103' does not appear in any peer-reviewed study, clinical trial registry, or regulatory database as of the current date, making its identity unverifiable.
- IGF-1 receptor signaling does drive muscle protein synthesis via the PI3K/Akt/mTOR pathway, so the basic biology the creator describes is real, but it does not validate an unidentified compound.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The compound 'IGF-103' does not appear in any peer-reviewed study, clinical trial registry, or regulatory database as of the current date, making its identity unverifiable.
- IGF-1 receptor signaling does drive muscle protein synthesis via the PI3K/Akt/mTOR pathway, so the basic biology the creator describes is real, but it does not validate an unidentified compound.
- A 2018 JAMA Internal Medicine investigation by Cohen et al. found widespread mislabeling in performance-enhancing products, a pattern that extends to gray-market injectable peptides.
- Post-exercise insulin sensitivity in skeletal muscle is documented (Richter and Hargreaves, 2013, Physiological Reviews), making the timing rationale physiologically grounded even if the compound itself is not verified.
- IGF-1 is FDA-approved only for specific pediatric growth conditions; its use for muscle building in healthy adults has no established long-term safety profile.
- Pollak (2012, Nature Reviews Cancer) identified IGF-1 signaling as a pathway with cancer promotion potential in the context of cell proliferation, a risk the video does not mention.
- Anyone considering a gray-market injectable should request a certificate of analysis from an independent third-party laboratory before use, and consult a licensed physician.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @landotalkspeps actually say?
The creator walked through a compound they called "IGF-103," describing it as something that "works directly at muscle cell level" by binding IGF-1 receptors, driving protein synthesis, and triggering hypertrophy pathways. They laid out a dosing progression starting at 20 to 40 micrograms, scaling to 60 to 80 micrograms, across an 8-week cycle with an 8-week break. They also covered reconstitution using bacteriostatic water and recommended post-workout timing based on insulin sensitivity and elevated muscle blood flow. The disclaimer at the end called it "educational purposes only."
That framing is worth noting upfront. Educational or not, a video with 56,000 views giving specific dose ranges and cycle protocols is functionally guiding people toward self-administering an unregulated injectable compound. That context matters for everything that follows.
Does the science back this up?
Here is the first problem: "IGF-103" does not appear in peer-reviewed literature, any known regulatory filing, or established peptide pharmacology references. The compound name itself is unverifiable. This is not a minor quibble. It is the foundational issue with this video.
IGF-1 (insulin-like growth factor 1) is a real, well-studied hormone. Its role in muscle protein synthesis and hypertrophy signaling through the PI3K/Akt/mTOR pathway is documented. Research by Goldspink (2005, Journal of Anatomy) and later work on mechano growth factor variants established that IGF-1 splice variants do play a role in muscle repair and growth. There are also analogs and truncated peptides in various stages of research. However, none of them are commercially available as "IGF-103." The creator appears to be describing something either mislabeled in the gray-market supply chain or invented outright. Either scenario is a serious red flag for anyone considering purchasing this.
What did they get wrong (or right)?
The mechanistic explanation, that IGF-1 receptors on muscle cells mediate protein synthesis and hypertrophy signaling, is broadly consistent with established endocrinology. That part is not wrong. The post-workout timing rationale, citing "insulin sensitive" muscles and elevated blood flow, also reflects real physiology. Insulin sensitivity in skeletal muscle is indeed elevated after resistance exercise, as shown by Richter and Hargreaves (2013, Physiological Reviews). Credit where it is due.
What they got wrong is more significant. The compound name "IGF-103" has no verifiable identity. The dosing protocol presented as common practice has no clinical trial backing it. The reconstitution guidance, while procedurally reasonable for peptide handling, is being applied to a substance of unknown composition and purity. And describing this compound as "a tool to amplify what your body's already doing" smooths over risks that include hypoglycemia, potential mitogenic effects, and the fact that gray-market injectables carry real contamination risks.
What should you actually know?
If you are searching for this compound because of this video, stop and do this one thing first: ask the seller for a certificate of analysis from a third-party lab. If they cannot provide one, you do not know what is in the vial. Gray-market peptide products have been found to contain incorrect concentrations, bacterial contamination, and in some cases entirely different compounds than labeled. A 2018 investigation by Cohen et al. (JAMA Internal Medicine) found widespread mislabeling in bodybuilding supplement products, a pattern that extends into the injectable peptide market.
IGF-1 itself is not an approved therapeutic for general muscle building in healthy adults. It is approved in specific pediatric growth disorders. Exogenous IGF-1 administration in healthy individuals carries theoretical cancer promotion risks given IGF-1's role in cell proliferation, a concern raised repeatedly in epidemiological literature including work by Pollak (2012, Nature Reviews Cancer). None of this means research into IGF-1 analogs is without merit. It means a TikTok video is not where you should be getting your safety framework.
- The compound name "IGF-103" is not found in clinical literature or regulatory databases.
- Post-workout timing logic is physiologically reasonable but applied to an unverified compound.
- Gray-market injectables carry contamination and mislabeling risks with no consumer protection.
- IGF-1 pathway manipulation in healthy adults has not been proven safe in long-term human trials.
Bottom line
The creator understands IGF-1 receptor biology well enough to sound credible. That is precisely what makes this video more dangerous, not less. Wrapping an unverifiable compound in accurate mechanistic language does not make the compound real or safe. FormBlends does not endorse sourcing, dosing, or cycling any compound that lacks a verified identity and peer-reviewed safety data in humans.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Lando · TikTok creator
56.8K views on this video
not medical advice, educational only #fyp #trending #gym #gymtok #educational
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about the compound 'igf-103' does not appear in any peer-reviewed study,?
The compound 'IGF-103' does not appear in any peer-reviewed study, clinical trial registry, or regulatory database as of the current date, making its identity unverifiable.
What does the video say about igf-1 receptor signaling does drive muscle protein synthesis via the?
IGF-1 receptor signaling does drive muscle protein synthesis via the PI3K/Akt/mTOR pathway, so the basic biology the creator describes is real, but it does not validate an unidentified compound.
What does the video say about a 2018 jama internal medicine investigation by cohen et al.?
A 2018 JAMA Internal Medicine investigation by Cohen et al. found widespread mislabeling in performance-enhancing products, a pattern that extends to gray-market injectable peptides.
What does the video say about post-exercise insulin sensitivity in skeletal muscle?
Post-exercise insulin sensitivity in skeletal muscle is documented (Richter and Hargreaves, 2013, Physiological Reviews), making the timing rationale physiologically grounded even if the compound itself is not verified.
What does the video say about igf-1?
IGF-1 is FDA-approved only for specific pediatric growth conditions; its use for muscle building in healthy adults has no established long-term safety profile.
What does the video say about pollak (2012, nature reviews cancer) identified igf-1 signaling as a?
Pollak (2012, Nature Reviews Cancer) identified IGF-1 signaling as a pathway with cancer promotion potential in the context of cell proliferation, a risk the video does not mention.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Lando, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.